Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.
Sunesis has built a highly experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer through:
Delivering on our Promise
Develop and commercialize medicines with significant potential to improve cancer care
Sunesis is developing vosaroxin in both AML and ovarian cancer.
Strategic alliances allow us to expand our development and marketing efforts.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.